Telangana Aligns with Biopharma SHAKTI to Position Hyderabad as Leading Life Sciences Hub

The programme seeks to move India beyond generics and position it as a global hub for innovation, alongside the removal of duties on costly cancer and rare disease drugs.

Telangana is strengthening its position as an integrated life sciences hub, hosting more than 2,000 companies and contributing nearly 35 percent of India’s pharmaceutical production, as it aligns with the Centre’s Biopharma SHAKTI initiative announced in the Union Budget 2026 27.

The state’s Next Gen Life Sciences Policy 2026 2030 aligns with the Biopharma SHAKTI programme, which aims to bolster domestic production of biologics and biosimilars.

Last month, Telangana launched the policy at the World Economic Forum in Davos, Switzerland, focusing on emerging areas including biologics and biosimilars.

The Centre has allocated Rs 10,000 crore for the Biopharma SHAKTI initiative. The programme seeks to move India beyond generics and position it as a global hub for innovation, alongside the removal of duties on costly cancer and rare disease drugs.

Telangana houses leading global pharmaceutical companies such as Amgen, Zoetis, Evernorth, HCA Healthcare, Eli Lilly and Sanofi. The state is expected to benefit from the scheme through its established industry clusters, research ecosystem and manufacturing capabilities.

Chief Minister A Revanth Reddy inaugurated BioAsia 2026 and invited leading biopharma companies to establish Global Capability Centres and invest in Hyderabad. He noted that several life sciences companies have already set up such centres in the city and proposed the development of a dedicated zone for GCCs within Bharat Future City.

In alignment with the Centre’s objective, the Telangana government will earmark dedicated land within the expanded Genome Valley to support biocatalysis, precision fermentation and next generation biomanufacturing under its life sciences policy.

Presenting the Budget 2026 27, Finance Minister Nirmala Sitharaman said, “BioPharma Shakti means BioPharma Strategy for Health Advancement through Knowledge, Technology and Innovation. India's digital disease burden is observed to be shifting towards non-communicable diseases like diabetes, cancer and autoimmune disorders.”

“Biologic medicines are key to longevity and quality of life at affordable costs. To develop India as a global biopharma manufacturing hub, I proposed the Biopharma Shakti with an outlay of Rs 10,000 crores over the next five years. This will build the ecosystem. For domestic production of biologics and biosimilars, the strategy will include a biopharma-focused network with three new national institutes of pharmaceutical education and research, popularly known as NIPERS, and upgrading seven existing ones," she said.

Stay tuned for more such updates on Digital Health News